-$0.59 EPS Expected for IsoPlexis Co. (NASDAQ:ISO) This Quarter

Equities analysts expect IsoPlexis Co. (NASDAQ:ISOGet Rating) to report earnings of ($0.59) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for IsoPlexis’ earnings, with estimates ranging from ($0.62) to ($0.56). The business is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that IsoPlexis will report full year earnings of ($2.41) per share for the current year, with EPS estimates ranging from ($2.51) to ($2.32). For the next year, analysts anticipate that the firm will post earnings of ($2.05) per share, with EPS estimates ranging from ($2.25) to ($1.65). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for IsoPlexis.

A number of analysts have issued reports on the company. Zacks Investment Research lowered IsoPlexis from a “buy” rating to a “hold” rating in a research note on Wednesday, February 16th. Morgan Stanley reduced their price objective on IsoPlexis from $17.00 to $12.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 15th. Finally, SVB Leerink reduced their price target on IsoPlexis from $20.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday, January 27th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, IsoPlexis currently has a consensus rating of “Buy” and an average price target of $14.44.

Shares of NASDAQ ISO traded up $0.19 during midday trading on Friday, reaching $2.04. 2,419 shares of the company were exchanged, compared to its average volume of 93,196. The company’s fifty day moving average is $3.68. IsoPlexis has a 1 year low of $1.62 and a 1 year high of $16.95. The company has a quick ratio of 9.88, a current ratio of 11.67 and a debt-to-equity ratio of 0.22.

Institutional investors and hedge funds have recently made changes to their positions in the business. Quadrant Private Wealth Management LLC acquired a new stake in shares of IsoPlexis during the 4th quarter valued at $102,000. Deutsche Bank AG acquired a new position in IsoPlexis during the fourth quarter worth $47,000. California State Teachers Retirement System acquired a new stake in shares of IsoPlexis in the fourth quarter valued at about $43,000. Citigroup Inc. acquired a new stake in shares of IsoPlexis in the fourth quarter valued at about $36,000. Finally, Northpond Ventures LLC acquired a new stake in IsoPlexis during the fourth quarter worth about $80,920,000. Institutional investors own 37.46% of the company’s stock.

IsoPlexis Company Profile (Get Rating)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea.

Further Reading

Get a free copy of the Zacks research report on IsoPlexis (ISO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IsoPlexis (NASDAQ:ISO)

Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with MarketBeat.com's FREE daily email newsletter.